Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2003
08/21/2003US20030157502 Induce apoptosis; antitumor, anticancer agents
08/21/2003US20030157487 Nucleic acid ligands
08/21/2003US20030157482 Binding labeled antibody to protein; measurement; calibration
08/21/2003US20030157225 Food product and process
08/21/2003US20030157204 A plant extracts as immunomodulator treating autoimmune disorders, antiallergens treating hypersensitivity reactions; used as pharmaceuticals, cosmetics or dietary supplements
08/21/2003US20030157200 Use of oligosaccharides to stimulate beta-endorphin production
08/21/2003US20030157199 A mixtures of animal extracts, plant extracts used as antidepressants, cognition activators for learning enhancement, and treating rheumatism diseases; comprising curcumin, and cholic acid, or scymnol, and flavonoids
08/21/2003US20030157198 Synergistic composition of trans-tetracos-15-enoic acid and Apocynin and method of treatment for hepatotoxicity
08/21/2003US20030157196 Compositions and methods for creating an air release mechanism to maintain skin health
08/21/2003US20030157191 Administering to a subject undergoing chemotherapy an amount of a chemoprotectant
08/21/2003US20030157187 Compositions and methods for treating or preventing inflammatory diseases
08/21/2003US20030157185 Treatment of symptoms of diseases relating to restricted blood flow to nerve endings and lower extremities such as fobromyalgia by topical application of composition comprising plant extracts
08/21/2003US20030157182 Pharmaceutical preparations and their manufacture
08/21/2003US20030157180 Suitable as depot formulation for administration via intramuscular or subcutaneous injection
08/21/2003US20030157179 Use of magnetic particles
08/21/2003US20030157177 In combination with a matrix vehicle selected from glycerol esters, hydrogenated oils, esterified polyethylene glycols, waxes and their mixtures
08/21/2003US20030157176 Silver-based antimicrobial agent which dissociates silver ions in water and silver ion trapping agent for trapping silver ions, comprising purine and pyrimidine bases, thiabendazole, and potassium iodide; external skin agents, cosmetics
08/21/2003US20030157173 Timed, sustained release systems for propranolol
08/21/2003US20030157171 Chitosan-xanthane hydrogel including in its matrix a poorly water soluble drug which upon swelling of hydrogel in aqueous medium becomes at least partially solubilized and releasable therefrom
08/21/2003US20030157169 Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2]oct-3-yl)acetonitrile monohydrochloride
08/21/2003US20030157168 Comprises releasable opioid agonist (morphine); for prevention of abuse
08/21/2003US20030157167 Oxymorphone controlled release formulations
08/21/2003US20030157166 Controlled release sulfonylurea formulation
08/21/2003US20030157165 Stable saccharide-free tablets comprising a salt of quinapril or moexipril
08/21/2003US20030157163 Semipermeable walled container housing capsule comprising progestin and estrogen for sustained-release via osmotic pressure changes within
08/21/2003US20030157161 Such as paclitaxel dispersed in micelle or liposome
08/21/2003US20030157159 Prevention and treatment of digestive tract infections
08/21/2003US20030157157 Such as progestins and estrogens; comprises sodium hydroxide as release agent; hormone replacement therapy; female contraception
08/21/2003US20030157156 Such as sodium hydroxide; sustained release; side effect reduction; urogenital disorders
08/21/2003US20030157155 Compositions for use as penetration promoters in transdermal formulations for highly lipophilic active ingredients
08/21/2003US20030157154 Compositions containing hydroxy aromatic aldehydes and their use in treatments
08/21/2003US20030157153 Tablets based on dissolution profiles, for once a day dosing without causing drug-induced hepatotoxicity
08/21/2003US20030157149 Absorbent articles containing additives
08/21/2003US20030157148 Methods for inhibiting the production of TSST-1
08/21/2003US20030157144 Desaturase genes and uses thereof
08/21/2003US20030157142 Implants with a phosphazene-containing coating
08/21/2003US20030157140 Parenteral preparation having structure of basement polymer layer, carrying layer containing objective substances selected from drugs, aroma chemicals, antigens; carrying layer sandwiched between basement and surface layers
08/21/2003US20030157138 Pharmaceutical or cosmetic carrier or composition for topical application onto skin and/or mucosal membranes; treatment of skin diseases or disorders including eczema, psoriasis and dermatitis
08/21/2003US20030157133 For treating, preventing, or inhibiting an infection or disease caused by a gram-positive organism including Streptococcus, Micrococcus, Lactobacillus, Staphylococcus, Bacillus, or Listeria
08/21/2003US20030157132 Remedies for hepatitis c
08/21/2003US20030157130 Modified to include heterologous insertion downstream of its replicase open reading frames; insertion preferably comprises one or more protein-coding regions ideal for virus-like particles packaging
08/21/2003US20030157124 Chlamydia membrane ATPase and corresponding DNA molecules, which can be used to prevent and treat Chlamydia infection in mammals such as humans
08/21/2003US20030157107 Agents for preventing or ameliorating insulin resistance and/or obesity
08/21/2003US20030157095 Invasive and metastic ability of breast cancer cells is proportional to level of peripheral type benzodiazepine receptor expressed, correlates with subcellular localization in that it is found in the nucleus of aggressive tumor cells
08/21/2003US20030157094 Prevention, therapy liver disorders, inflammatory bowel diseases, Crohn's disease; antiulcer agents; rheumatic diseases
08/21/2003US20030157090 Redox systems; accumulation of polypeptide in plant cell; genetic engineering
08/21/2003US20030157088 Mixture of enzyme and enzyme inhibitors
08/21/2003US20030157086 Administering antagonist to sphingomyelinase gene product;side effect reduction of cancer therapy
08/21/2003US20030157083 Mixture with gelatin capsules; low temperature; human absorption
08/21/2003US20030157067 Mixture of bacteria culture product, sugar, carrier and flavor
08/21/2003US20030157061 Analgesics, antiinflammatory agents, cardiovascular disorders; anticancer agents
08/21/2003US20030157056 Modified cytokines for use in cancer therapy
08/21/2003US20030157055 Modified cytokines for use in cancer therapy
08/21/2003US20030157053 Administering mixture of apotosis agent and neutralizer thereof
08/21/2003US20030157052 Prodrug for in situ regeneration; water solubility
08/21/2003US20030157046 Discoloration inhibition, oxidation resistance
08/21/2003US20030157037 Use of aryl oximes for the prophylaxis and/or treatment of erythema formation and/or inflammatory reaction of the skin
08/21/2003US20030157036 Topical dapsone for the treatment of acne
08/21/2003US20030157032 Antihistamines, bronchodilator agents, antiinflammatory agents; mixture of drug and propellant
08/21/2003US20030157030 Methods and compositions for therapeutic use of rna interference
08/21/2003US20030157029 Methods of administering and enhancing absorption of pharmaceutical agents
08/21/2003US20030157028 Formulations containing an anticholinergic drug for the treatment of chronic obstructive pulmonary disease
08/21/2003US20030157027 Administering mixture of biocompatibility polymer and contrast agent
08/21/2003US20030154974 Forming flour from the cereal grain, mixing the flour with water to form a slurry of aqueous solution of beta-glcan and solid residue, separating solution from solid residue, dehydrating to form gel or solid beta-glucan
08/21/2003DE19937304C2 Verwendung von CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen Use of CGRP antagonists for the control of menopausal hot flushes
08/21/2003CA2516331A1 Combination therapy using glycosaminoglycans and therapeutic agents for the treatment of respiratory disorders
08/21/2003CA2476618A1 Phenalenone derivatives, method for the production thereof and use of the same
08/21/2003CA2476530A1 Methods for producing interfering rna molecules in mammalian cells and therapeutic uses for such molecules
08/21/2003CA2476454A1 Use of inhibitors of the sodium-dependent chloride-bicarbonate-exchanger for treating thrombotic and inflammatory diseases
08/21/2003CA2476446A1 Use of sodium/hydrogen exchange inhibitors from the treatment of thrombotic and inflammatory diseases
08/21/2003CA2476424A1 Means and methods for altering the motility of the gastrointestinal tract
08/21/2003CA2476383A1 Carbohydrate-based anti-wrinkle and tissue remodelling compounds
08/21/2003CA2476366A1 Cancer therapy
08/21/2003CA2476282A1 Dosing regimen for gemcitabine hcv therapy
08/21/2003CA2476279A1 Modified fluorinated nucleoside analogues
08/21/2003CA2476223A1 Macrolide antibacterial compounds
08/21/2003CA2476162A1 Jnk inhibitor
08/21/2003CA2476120A1 Methods and compositions for the treatment of eye diseases
08/21/2003CA2476113A1 Beta-sheet mimetics and composition and methods relating thereto
08/21/2003CA2476027A1 Alpha-substituted arylalkyl phosphonate derivatives
08/21/2003CA2476017A1 Preparations containing folic acid, vitamin b6, and vitamin b12, and use thereof
08/21/2003CA2476000A1 Methods and compositions for treating hyperproliferative conditions
08/21/2003CA2475972A1 Enzyme treatment of foodstuffs for celiac sprue
08/21/2003CA2475971A1 Methods of reducing rhinovirus contagion and related compositions
08/21/2003CA2475928A1 Inhibition of lung metastases by aerosol delivery of p53 gene and anti-cancer compounds
08/21/2003CA2475882A1 Alpha-substituted heteroarylalkyl phosphonate derivatives
08/21/2003CA2475880A1 Novel tricycloimidazoline derivatives, method for production and use thereof as medicaments
08/21/2003CA2475838A1 Cytotoxic t-cell epitopes from chlamydia
08/21/2003CA2475825A1 Tricyclic n-acyl compounds
08/21/2003CA2475783A1 Benzenesulfonamide derivatives as antipsychotic agents
08/21/2003CA2475770A1 Microglia inhibitors for interrupting immune reactions induced by interleukin 12 and ifn.gamma.g(g)
08/21/2003CA2475768A1 Methods of inhibiting hiv-1 vpr activity and hiv-1 infectivity using atr or rad17 inhibitors
08/21/2003CA2475763A1 Methods of treating attention deficit/hyperactivity disorder (adhd)
08/21/2003CA2475722A1 Formulations of atorvastatin stabilized with alkali metal additions
08/21/2003CA2475708A1 Nicotinamide derivatives useful as pde4 inhibitors
08/21/2003CA2475703A1 Aryl ureas with angiogenesis inhibiting activity
08/21/2003CA2475659A1 Pharmaceutical composition comprising n- ((1-n-butyl-4-piperidinyl) methyl)-3, 4-dihydro-2h- (1, 3) oxazino (3, 2-a) indole-10-carboxamide or salt and process therefor comprising dry granulation
08/21/2003CA2475592A1 Powder composition comprising zaleplon of defined particle size distribution and pharmaceutical products made therefrom
08/21/2003CA2475545A1 Use of anethole dithiolethione in lung cancer chemoprevention
08/21/2003CA2475544A1 Oral dosage form for controlled drug release
1 ... 5369 5370 5371 5372 5373 5374 5375 5376 5377 5378 5379 5380 5381 5382 5383 5384 5385 5386 5387 5388 5389 ... 7860